Physician profile
Mohammad Omaira
NPI 1982884128
$3,565.11
in general payments reported to CMS, 2019-2025
36 companies · $405 in 2025
The $405 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,063 · 2020: $164 · 2021: $15.41 · 2022: $117 · 2023: $268 · 2024: $532 · 2025: $405.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,011 · Education: $195.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,010.60 |
| Education | $194.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tosoh Bioscience, INC. | $1,632.00 | 2019 | |
| Novartis Pharmaceuticals Corporation | $280.24 | 2019-2025 | |
| Genentech USA, INC. | $168.02 | 2019-2025 | Venclexta, Polivy |
| Pharmacyclics LLC, An Abbvie Company | $154.99 | 2019-2023 | Imbruvica |
| Astellas Pharma US INC | $151.94 | 2019-2024 | Xtandi |
| Amgen INC. | $113.99 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $89.56 | 2019-2025 | Keytruda, Lynparza |
| Celgene Corporation | $77.41 | 2019-2024 | Pomalyst |
| Beigene USA, INC. | $76.34 | 2023-2024 | Brukinsa |
| Takeda Pharmaceuticals U.S.A., INC. | $63.23 | 2024-2025 | Fruzaqla, Iclusig |
| Glaxosmithkline, LLC. | $60.74 | 2020-2025 | Ojjaara, Jemperli, Zejula |
| Astrazeneca Pharmaceuticals LP | $57.44 | 2019 | |
| Gilead Sciences, INC. | $54.22 | 2023-2024 | Trodelvy |
| Janssen Biotech, INC. | $51.94 | 2019-2025 | Carvykti |
| Eisai INC. | $51.66 | 2024-2025 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Incyte Corporation | $43.35 | 2019-2024 | Jakafi |
| Karyopharm Therapeutics INC. | $39.28 | 2020-2025 | Xpovio |
| Genzyme Corporation | $34.02 | 2019 | |
| Springworks Therapeutics, INC. | $31.96 | 2024 | Ogsiveo |
| Pfizer INC. | $30.51 | 2019-2023 | |
| Jazz Pharmaceuticals INC. | $28.69 | 2022 | |
| Csl Behring | $28.46 | 2019 | |
| Abbvie INC. | $27.75 | 2024 | |
| Ipsen Biopharmaceuticals, INC | $27.69 | 2024 | Onivyde |
| Regeneron Healthcare Solutions, INC. | $26.94 | 2019 | |
| Adc Therapeutics America, INC. | $25.10 | 2024 | |
| Sun Pharmaceutical Industries INC. | $23.40 | 2025 | |
| Progenics Pharmaceuticals, INC. | $20.36 | 2024 | |
| Puma Biotechnology, INC. | $20.21 | 2022 | |
| Syndax Pharmaceuticals, INC. | $16.51 | 2025 | |
| Mirati Therapeutics, INC. | $16.33 | 2023 | Krazati |
| Rigel Pharmaceuticals, INC. | $14.60 | 2025 | Gavreto, Tavalisse, Rezlidhia |
| Lilly USA, LLC | $13.13 | 2024 | Verzenio, Jaypirca |
| Shire North American Group INC | $13.10 | 2019 |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mohammad Omaira listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.